Seminars in Oncology Nursing
Volume 23, Supplement 2 , Pages S17-S22, November 2007

Challenges of Oral Medications in Patients With Advanced Breast Cancer

  • Frances M. Palmieri

      Affiliations

    • Corresponding Author InformationAddress correspondence to Frances M. Palmieri, RN, MSN, OCN®: Breast Clinic and Breast Cancer Program, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224
  • ,
  • Debra L. Barton

Objectives

To list methods that nurses can use to monitor and ensure compliance with an oral agent for the treatment of metastatic breast cancer.

Data Sources

Published research articles, abstracts, and clinical experience.

Conclusion

Oral chemotherapeutic agents offer the advantages of patient control and less interference with administration and, frequently, improved tolerability profiles versus conventional infusion chemotherapy. However, there is the difficulty of ensuring optimal adherence to the treatment plan. Adherence rates for oral chemotherapy vary widely in studies, and can depend on psychological and socioeconomic factors as well as individual patient outcome expectations.

Implications for Nursing Practice

Oncology nurses can identify factors influencing adherence to therapy and assess those patients appropriate for oral therapy. Oncology nurses can facilitate follow-up visits, ask appropriate adherence questions, and successfully manage the shift of administration responsibility to the patient.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The development of this article was based on a presentation given by F. Palmieri at the 2006 Oncology Nursing Society's 7th Annual Institutes of Learning; F. Palmieri received an honorarium through an educational grant from GlaxoSmithKline.

PII: S0749-2081(07)00091-5

doi:10.1016/j.soncn.2007.10.004

Seminars in Oncology Nursing
Volume 23, Supplement 2 , Pages S17-S22, November 2007